Steven M. Greenberg, MD, PhD, FAHA, Chair; Wendy C. Ziai, MD, MPH, FAHA, Vice Chair;
Charlotte Cordonnier, MD, PhD; Dar Dowlatshahi, MD, PhD, FAHA; Brandon Francis, MD …

Intracerebral hemorrhage (ICH) is a devastating form of stroke with high morbidity and
mortality. This review article focuses on the epidemiology, cause, mechanisms of injury …

Background: Andexanet alfa is a modified recombinant inactive factor Xa (FXa) designed to
reverse FXa inhibitors. ANNEXA-4 (Andexanet Alfa, a Novel Antidote to the Anticoagulation …

Abstract Background/Objective There are limited data on the risks and benefits of using
andexanet alfa (AA) in comparison with four-factor prothrombin complex concentrate (4F …

Background and Purpose: Andexanet alfa is a recombinant modified human FXa (factor Xa)
developed to reverse FXa inhibition from anticoagulants. Hemostatic efficacy and reversal of …

Background and Purpose: It is unestablished whether andexanet alfa, compared with
guideline-based usual care including prothrombin complex concentrates, is associated with …

OBJECTIVES: To combine evidence on andexanet alfa and prothrombin complex
concentrates for factor Xa inhibitor-associated bleeding to guide clinicians on reversal …

Importance Although the use of factor Xa (FXa) inhibitors has increased substantially over
the past decade, there are limited data on characteristics and outcomes of FXa inhibitor …

Aim: We describe the real-world utilization and outcomes associated with managing oral
factor Xa inhibitor (FXai)-related major bleeds. Materials & methods: Electronic records from …

Abstract Background Oral factor Xa inhibitors (FXaI) can be administered in fixed doses
without the need for routine laboratory monitoring. Anti-Xa assays can estimate …